Key facts
- This page summarizes Pascal Bamford's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Sep 2024, 21:41.
Pascal Bamford - 29 Aug 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)
- Reporting relationship
- Chief Clinical Officer
- Issuer ticker
- AKYA
- Reported as of
- 29 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Sep 2024, 21:41:14 UTC
- Next SEC filing
- 21 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Pascal Bamford by Brian McKelligon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Pascal Bamford filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 03 Sep 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKYA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- +48%
- Price
- $0.000000
- Shares after
- 122,758
- Date
- 29 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The restricted stock units shall vest in full on the second anniversary of the first day of the month subsequent to the date of grant.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.